Manufacture of a lyophilized subcutaneous injection from the live ovine/caprine streptococcosis septicemia vaccine API begins with separation of the bacterial biomass from the fermentation broth via tangential-flow filtration using a polyethersulfone membrane with a 0.1 µm nominal cutoff; the retentate is then diafiltered against 3 volumes of phosphate-buffered saline at pH 7.2 ± 0.2 to remove residual media components that would otherwise destabilize the freeze-dried cake. The manufacturing dossier for this dosage form is structured against USDA 9 CFR Part 113 live bacterial vaccine requirements, VICH GL44 stability testing expectations, and ISO 13408-1:2008 aseptic processing clauses. The antigen suspension is adjusted to a pre-lyophilization viable count of 1.0×10⁹–1.0×10¹⁰ CFU/mL using cold Water for Injection, and mixed with an equal volume of a stabilizer concentrate containing 10.0% w/v sucrose, 4.0% w/v hydrolyzed gelatin, 2.0% w/v sodium L-glutamate, and 1.0% w/v potassium dihydrogen phosphate. This yields a final fill suspension containing 5.0% w/v sucrose, 2.0% w/v gelatin, 1.0% w/v sodium L-glutamate, and 0.5% w/v phosphate buffer, with a fill volume of 2.0 mL per 10-dose type I glass vial; after reconstitution in 20 mL sterile saline, each 1.0 mL dose delivers 1×10⁷–1×10⁸ CFU, but the minimum protective count is established for each serial through vaccination-challenge studies because the pharmacopoeial standards do not fix a universal potency value for this antigen. Aseptic filling is performed in a Grade A environment conforming to ISO 14644-1:2015 Class 5 at rest and Class 7 background, with laminar airflow velocity of 0.36–0.54 m/s and continuous particle monitoring at 0.5 µm and 5.0 µm; process simulation batches demonstrate ≤1 contaminated unit per 10,000 filled vials. The vials are partially stoppered with bromobutyl lyophilization stoppers and transferred to a shelf lyophilizer with a condenser capacity of 30 kg ice per cycle. The freezing program ramps shelf temperature from +4 °C to −45 °C at 0.8 °C/min and holds for 4 h to ensure complete solidification; primary drying at −25 °C and 0.150 mbar continues for 18–24 h until product temperature reaches −20 °C as measured by thermocouple or Pirani/capacitance manometer differential; secondary drying at +25 °C and 0.050 mbar proceeds until the residual moisture by Karl Fischer titration (USP <921> Method Ia) is ≤3.0% w/w. Terminal product is a uniform off-white lyophilized plug for subcutaneous injection, packaged under vacuum in 10-dose and 50-dose vials and stored at 2–8 °C; reconstituted vaccine must be used within 2 h at 20–25 °C because the live bacterium loses 0.3–0.6 log10 within the first hour.

What Limits Live Antigen Viability in High-Ionic-Strength Oral Drench Solutions?

In a liquid oral drench, the live antigen is exposed to ionic strength, dissolved oxygen, and antimicrobial preservatives that are not present in lyophilized forms. The solution is manufactured as a non-sterile veterinary biological product under USDA 9 CFR Part 113 if marketed in the United States; if marketed in territories recognizing Ph. Eur. monographs, the relevant monograph and Ph. Eur. 5.1.4 for microbiological quality of non-sterile dosage forms are applied. Antimicrobial effectiveness testing is performed according to USP <51>, but preservatives such as benzyl alcohol are generally excluded because they reduce live cell recovery by more than 0.5 log10 within 24 h. The vehicle comprises 0.6% w/v sodium chloride, 0.4% w/v potassium dihydrogen phosphate, 1.5% w/v bacteriological peptone, 0.3% w/v sodium carboxymethylcellulose, and 0.1% w/v polysorbate 80 in demineralized water at pH 7.0 ± 0.2. The lyophilized API powder is reconstituted aseptically to 1.0×10⁸ CFU/mL, and the fill is 2.0 mL per lamb/kid dose, giving 2×10⁸ CFU per administration. The vehicle is sterilized by autoclaving at 121 °C for 15 min and cooled under nitrogen overlay; the dried antigen is added through a sterile transfer port and dispersed with a bottom-mount high-torque disperser at 800 rpm for 10 min; the dispersion is filled volumetrically into 500 mL high-density polyethylene bottles with tamper-evident caps at 2–8 °C. The terminal product type is an oral drench solution for lambs and kids, packed as 100-dose, 250-dose, and 1,000-dose containers; in-use shelf life after broaching is 4 h at 20–25 °C or 8 h refrigerated, because viability loss follows first-order decay with a k value of approximately 0.15 h⁻¹ at ambient temperature. Chlorinated mains water must never be used for dilution; free chlorine residual above 0.2 ppm reduces viable count by 1 log10 in 30 min.

Because oral administration via balling gun or dosing syringe reduces aerosol exposure and allows direct mucosal contact, a rapidly disintegrating effervescent tablet format has been adapted for the live ovine/caprine streptococcosis septicemia antigen. Tablet quality is controlled by USP <701> disintegration, USP <1216> friability, and Ph. Eur. 2.9.1; moisture uptake is monitored by USP <921> Method Ia. The direct-compression formula uses 0.5–2.0% w/w lyophilized antigen powder standardized to 1.0×10¹⁰ CFU/g, 35–45% w/w anhydrous citric acid, 25–35% w/w sodium bicarbonate, 10–20% w/w lactose monohydrate, 2–5% w/w polyethylene glycol 6000, and 0.5% w/w magnesium stearate. A 1.5 g tablet therefore contains 7.5–30 mg of antigen powder and delivers 7.5×10⁷–3.0×10⁸ CFU, subject to lot-specific standardization; published tablet-specific viability data for this exact antigen are limited, so the process is qualified by pilot batch stability rather than transferred from literature. The dry ingredients are blended in a 100 L bin blender at 15 rpm for 20 min; the antigen powder is added last to minimize shear. Tablets are compressed on a 12-station rotary tablet press equipped with 18 mm flat-faced bevel-edge tooling at 8–12 kN compression force and 25–30 rpm turret speed. Target hardness is 30–50 N, friability ≤0.5%, and disintegration time in 200 mL water at 37 °C is ≤3 min. The terminal product types are effervescent oral tablets or boluses for lambs and kids, packaged in aluminum/aluminum strip blisters containing 1 g desiccant sachets; the product is stored below 25 °C and protected from moisture. Humidity above 30% RH during compression and packaging is not permitted because sodium bicarbonate and citric acid react prematurely, generating carbon dioxide and reducing tablet porosity.

Enteric Capsule Granulation and Delayed-Release Barriers for Ruminant Oral Vaccination

Ruminant oral vaccination with enteric-coated capsules requires protecting the live bacterium from degradation in the abomasal acid environment while permitting release in the small intestine. Compliance for the capsule route is aligned with USP <711> dissolution for delayed-release solid oral dosage forms, Ph. Eur. 2.9.1 disintegration, and 9 CFR Part 113 live bacterial vaccine identity and purity requirements if distributed in the United States. The enteric coating process is qualified by an acid-resistance test in 0.1 N HCl for 2 h followed by phosphate buffer at pH 6.8; not more than 10% of antigen is released in acid, and not less than 75% is released within 45 min at buffer pH. Granules are manufactured with 1.0–3.0% w/w lyophilized antigen powder, 40–60% w/w microcrystalline cellulose, 15–25% w/w lactose monohydrate, 5–10% w/w hydroxypropyl methylcellulose E5 as binder, and 5% w/w croscarmellose sodium. The wet mass is extruded through a 1.0 mm screen, spheronized, and dried to 2.5% w/w moisture. The dried granules are filled into size 7 hard gelatin capsules at 250 mg net fill, giving 2.5–7.5 mg active powder and 2.5×10⁷–7.5×10⁷ CFU per capsule based on a 1.0×10¹⁰ CFU/g antigen powder. Published data for the exact viable count recovered from the sheep small intestine from this vaccine are limited; therefore release is verified by in vitro dissolution and viability is confirmed by plate count on blood agar before and after the acid-resistance step.

Coating is performed in a 24-inch perforated pan with inlet air at 30±2 °C, atomizing air pressure 1.5 bar, and spray rate 8–10 g/min using an aqueous dispersion of methacrylic acid-ethyl acrylate copolymer Type B to a weight gain of 8–10%. The coated capsules are dried at 25 °C for 12 h, then sealed in foil strips with 2 g silica gel. Terminal product types are enteric-coated capsules for oral administration to lambs and kids, and enteric-coated granules for mixing into liquid feed immediately before administration; capsules should not be opened or crushed before administration because the unprotected antigen loses 1–2 log10 within 5 min at pH 2.0.

For mass vaccination campaigns where individual animal handling is impractical, the live antigen can be formulated as a dry granulated premix for incorporation into pelleted creep feed or milk replacer. Feed premix production operates under ISO 22000:2018 food safety management systems and Hazard Analysis and Critical Control Points per the Codex Alimentarius General Principles of Food Hygiene; the biological component remains under 9 CFR Part 113 if marketed in the United States, and the final feed must meet 21 CFR 225 current good manufacturing practice for medicated feeds when applicable, although a live vaccine premix is not classified as a medicated feed additive in all jurisdictions. The premix carrier consists of 60–70% w/w ground corncob grit, 20–30% w/w sucrose, 5–10% w/w spray-dried skimmed milk powder, and 1–5% w/w lyophilized antigen powder; the carrier is sized to 500–1000 µm to minimize segregation. The premix is incorporated at 0.5–1.0 kg per metric ton of finished feed, resulting in 1.0×10⁷–5.0×10⁷ CFU/kg of feed, with a target intake of 100–200 g per lamb/kid per day for 3 consecutive days. Blending is performed in a double-ribbon mixer of 500 kg capacity at 30 rpm for 15 min, with the antigen powder added after a 5 kg pre-blend with sucrose to avoid concentrated pockets. The premix is mixed into the finished feed in a horizontal paddle mixer for 10 min. If pelleted, the feed is conditioned at 55–65 °C for 10–20 s and pressed through a 4 mm die; post-pellet viability loss must be ≤0.5 log10. Extrusion above 85 °C is not used because shear and heat together reduce viable count by 1–2 log10. Terminal product types are dry granulated premix packed in 10 kg and 25 kg triple-layer paper bags with polyethylene liner, and terminal feed forms include meal, 3–4 mm pellets, and creep feed for lambs and kids; the premix should not be pelleted with steam above 70 °C or stored above 30 °C for more than 30 days.

When Drinking Water Medication Is the Only Practical Route for Large Flocks

Drinking water delivery of a live bacterial vaccine requires continuous neutralization of disinfectant residues, maintenance of buffered pH, and rapid voluntary consumption to limit post-dilution viability loss. Water quality for this route is checked against USP <1231> for water for pharmaceutical purposes and ISO 19458:2006 for sampling, with residual free chlorine measured by APHA 4500-Cl G DPD colorimetric method; the target water has 0.0 ppm free chlorine, ≤0.3 ppm iron, ≤0.05 ppm copper, and pH 6.5–7.5. The stock solution label conditions follow USDA 9 CFR Part 113 for use directions, and disposal follows local veterinary biological waste regulations. The lyophilized antigen powder is reconstituted in a stock solution at 1.0×10⁷ CFU/mL using chilled, non-chlorinated water containing 0.2% w/v skimmed milk powder as a neutralizer of heavy metals and 0.1% w/v sodium thiosulfate to quench chlorine. The stock solution is proportioned into drinking water at 1:100 to 1:200, delivering 5.0×10⁴–1.0×10⁵ CFU/mL in the drinking line; each lamb/kid consumes 100–200 mL over 2 h, giving 5.0×10⁶–2.0×10⁷ CFU per animal. The stock solution is prepared in a 200 L jacketed stainless steel tank with a paddle agitator at 100 rpm for 5 min; the antigen is added aseptically after the excipients are dissolved and cooled to 4–8 °C. A piston-driven proportioner pump calibrated to 1:128 injects stock into the main drinking line; the line is flushed with non-chlorinated water for 10 min before and after the medication period. Terminal product types are stock solutions in 1 L and 5 L HDPE jerricans or bags, and the final medicated water is administered within 2–4 h of dilution. If free chlorine exceeds 0.2 ppm or pH falls below 5.5 or rises above 8.5, the viability loss exceeds 1 log10 in 30 min; therefore in-line chlorine filters and citric acid/sodium bicarbonate correcting solutions are required on farms with variable water quality.